Details of the National Institutes of Health-funded study were published this week in a Nature paper titled A brain reward circuit inhibited by next-generation weight-loss drugs in mice. In it, the team reported that they investigated the small-molecule GLP-1s including Eli Lillys recently approved drug orforglipron, also known by the brand name Foundayo, as well as danuglipron, an oral GLP-1 that was being developed by Pfizer until the company decided to discontinue its development in 2025
PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan), regardless of your surgical history or dose level
Supports antioxidant activity*
GLP-1 Receptor Agonists: A Different Class of Weight Loss Medication Semaglutide and tirzepatide belong to the glucagon-like peptide-1 receptor agonist family, medications that mimic natural hormones controlling blood sugar and appetite
Your provider may recommend starting GLP-1 medications at lower doses, taking metformin with food, or adjusting timing to improve tolerability
